We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics

Download Mobile App





New CE-Marked ELISA Test Detects COVID-19 Antibodies in Recently Infected People with Mild Symptoms

By LabMedica International staff writers
Posted on 28 Aug 2020
Print article
Image: New CE-Marked ELISA Test Detects COVID-19 Antibodies in Recently Infected People with Mild Symptoms (Photo courtesy of The Binding Site)
Image: New CE-Marked ELISA Test Detects COVID-19 Antibodies in Recently Infected People with Mild Symptoms (Photo courtesy of The Binding Site)
A new test can detect COVID-19 antibodies in people with recent exposure who have mild symptoms.

The SARS-CoV-2 Antibody ELISA assay which focuses on mild non-hospitalized patient blood samples has been developed by The Binding Site (Birmingham, UK) and the University of Birmingham’s Clinical Immunology Service (Birmingham, UK) with the initial antigen being provided by the University of Southampton (Southampton, UK). Earlier this year, researchers from the University of Southampton had revealed the fundamental properties of the protein “spike” on the surface of the coronavirus. This has enabled them to produce almost exact copies of the protein which they provided to the Birmingham teams to develop their antibody tests.

The new test specifically detects antibodies (IgG, IgA, and IgM) to the SARS-CoV-2 trimeric spike protein, which is an important protein for the virus infectivity. Targeting IgG, IgA, and IgM the assay will cover all the immunoglobulins which are vital in the body’s fight against this virus. These three antibodies appear at different times after infection. The test was designed to detect all three, to increase detection at the earliest possible stage after exposure to the virus. The test was developed using over 800 blood samples taken from people who had mild to moderate disease. It is already being used in many clinical studies and is expected to be rapidly adopted by surveillance teams seeking to understand the distribution of infection in the population, as well as vaccine researchers who need to assess antibody responses in clinical trials.

“The creation of sensitive antibody tests relies on being able to create accurate mimics of components of the virus. We have been delighted to help setup the Binding Site’s COVID-19 antibody test by manufacturing the SARS-CoV-2 viral spike glycoprotein for the clinical and academic partners at the University of Birmingham,” said Max Crispin, Professor of Glycobiology at the University of Southampton.

“Humans make three types of antibodies – Anti-IgM, IgG and IgA. IgM tends to appear first, and IgG and lgA tend to appear later. By combining all three The Binding Site test is able to detect COVID-19 infection in people who have only recently been exposed, or who have mild symptoms,” said Professor Adam Cunningham, Professor of Functional Immunity at the University of Birmingham.

“We set out to develop a test with the University of Birmingham that would detect COVID-19 early, and validated the test in a non-hospitalized population that had mild symptoms - which is the largest target population for COVID-19 testing - and we designed the testing kit so it can be used by any laboratory in the world,” added Dr. Stephen Harding, Chief Scientific Officer at The Binding Site.

Related Links:
University of Southampton
The Binding Site
University of Birmingham



Print article
BIOHIT  Healthcare OY

Channels

Molecular Diagnostics

view channel
Image: Photomicrograph of histology of a Ewing sarcoma in lung. The PAS stain highlights glycogen and the staining was negative with a PAS diastase stain (Photo courtesy of Nephron).

Comprehensive Molecular Profiling Matches Pediatric Patients to Therapies

A major challenge of using a comprehensive profiling approach for precision medicine is separating pathogenic from non-pathogenic molecular changes within a tumor. A program has been presented of the... Read more

Industry News

view channel
Image: Mindray Hematology Solution Helps High-Volume Lab Run 2,820,000 CBC Tests Annually (Photo courtesy of Mindray)

Mindray Hematology Solution Helps High-Volume Lab Run 2,820,000 CBC Tests Annually

High-volume laboratories face several challenges, including high instrument failure rate, errors due to several manual steps, low efficiency and long TAT, and heavier workload for the lab staff.... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.